Coinbase provides five-point spot Ethereum ETF application reason to the US SEC: shares that can be classified as commodity-based trusts
This week Coinbase met with U.S. Securities and Exchange Commission (SEC) officials to discuss rule changes to launch a spot ether exchange-traded fund (ETF). According to a meeting transcript shared by the SEC, Coinbase offered five spots for spot ether. The reasons for applying for Bitcoin ETF mainly include: 1. The shares of the spot Ethereum ETF can be classified as commodity-based trust shares; 2. The reasons for the US Securities and Exchange Commission’s approval of the spot Bitcoin ETP have the same or greater effect on Ethereum. ; 3. Ethereum’s mechanism can significantly limit ETH’s sensitivity to fraud and manipulation; 4. The performance of the Ethereum spot market has highly demonstrated that the market is resistant to fraud and manipulation; 5. Like Bitcoin, exchanges A comprehensive surveillance sharing agreement with the Chicago Mercantile Exchange (CME) will help monitor fraud and manipulation.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.
After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.
Crypto prices
More
